Rainer R. Kuhn

Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition

P. Svenningsson, D. Steindler, I. Blockx, 2018, Proceedings of the National Academy of Sciences.

Optimization of an HTRF Assay for the Detection of Soluble Mutant Huntingtin in Human Buffy Coats: A Potential Biomarker in Blood for Huntington Disease

H. D. Rosas, M. DiFiglia, S. Hersch, 2010, PLoS currents.

LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington’s Disease

A. Young, S. Hersch, A. Kazantsev, 2016, Journal of Huntington's disease.

Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients.

S. Tabrizi, D. Langbehn, B. Leavitt, 2015, The Journal of clinical investigation.

Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression.

S. Tabrizi, R. Scahill, G. Bates, 2012, The Journal of clinical investigation.